Follow
Fortunato Ciardiello
Fortunato Ciardiello
Professore di oncologia medica, seconda università di napoli
Verified email at unina2.it
Title
Cited by
Cited by
Year
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ...
The Lancet 389 (10066), 255-265, 2017
45722017
Epidermal growth factor-related peptides and their receptors in human malignancies
DS Salomon, R Brandt, F Ciardiello, N Normanno
Critical reviews in oncology/hematology 19 (3), 183-232, 1995
37291995
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
33912016
EGFR antagonists in cancer treatment
F Ciardiello, G Tortora
New England Journal of Medicine 358 (11), 1160-1174, 2008
26022008
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
25612010
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS …
E Van Cutsem, CH Köhne, I Láng, G Folprecht, MP Nowacki, S Cascinu, ...
J Clin Oncol 29 (15), 2011-2019, 2011
23062011
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
18242012
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
F Ciardiello, G Tortora
Clinical Cancer Research 7 (10), 2958-2970, 2001
14252001
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ...
Clinical Cancer Research 6 (5), 2053-2063, 2000
13042000
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
11972019
Chronic inflammation and oxidative stress in human carcinogenesis
A Federico, F Morgillo, C Tuccillo, F Ciardiello, C Loguercio
International journal of cancer 121 (11), 2381-2386, 2007
11882007
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
9382016
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
EV Cutsem, HJ Lenz, CH Kohne, V Heinemann, S Tejpar, I Melezínek, ...
9092015
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six …
D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ...
Annals of oncology 28 (8), 1713-1729, 2017
8682017
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ...
Clinical cancer research 7 (5), 1459-1465, 2001
8152001
Treatment of gastric cancer
M Orditura, G Galizia, V Sforza, V Gambardella, A Fabozzi, MM Laterza, ...
World journal of gastroenterology: WJG 20 (7), 1635, 2014
7832014
Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials
S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ...
JAMA oncology 3 (2), 194-201, 2017
7652017
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ...
Cancer research 62 (24), 7284-7290, 2002
7092002
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials
C Bokemeyer, E Van Cutsem, P Rougier, F Ciardiello, S Heeger, ...
European journal of cancer 48 (10), 1466-1475, 2012
6962012
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
W De Roock, V De Vriendt, N Normanno, F Ciardiello, S Tejpar
The lancet oncology 12 (6), 594-603, 2011
6912011
The system can't perform the operation now. Try again later.
Articles 1–20